Immuno-Oncology - Thematic Research
Summary
The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer
Checkpoint modulation is the most valuable IO sector
Within 2021-2022, the next immuno-oncology breakthrough has not happened
High cost of therapy and need for personalized treatment using biomarkers remain as unmet needs
Scope
- Overview of immuno-oncology including classification of therapy and technologies, regulatory and market access details, product & company profiles.
- Quotes from US- and 5EU-based key opinion leaders and payers.
- Key topics covered for IO in the 8MM include trends, value chain, market analysis, opportunities, challenges and unmet needs and high-value deals.
- Pipeline analysis: Comprehensive data split across different phases and indications, emerging novel trends under development, and analysis of the most promising late-stage pipeline drugs for each class of IO (Phase II - III).
- Analysis of the key dynamics of the IO market. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered in detail to highlight business opportunities.
- Robust analysis of high-prescriber survey conducted with 80 oncologists.
- What impact will late-stage pipeline agents have on the market? Which class of IO drugs will have the highest peak sales, and why?
- What are the current unmet needs in IO, which pipeline agents or strategies are positioned to counter these unmet needs? What are the opportunities for R&D?
- How is the field of checkpoint modulation going to move forward? Which technologies are the most promising for combinations?
- What is the regulatory landscape for IO agents in the US, the 5EU Japan, and China?
- What is the current and future outlook of IO according to high prescribers?
- Executive Summary
- Immuno-oncology Overview
- What is Immuno-oncology
- What is Immuno-oncology According To Regulators
- What is Immuno-oncology
- Most Important Milestones of Immuno-oncology Development Globally
- Key Twitter Chat
- Trends
- Industry Trends - Bispecific Antibodies
- Industry Trends - Cancer Vaccines
- Industry Trends - Cell Therapies
- Industry Trends - Checkpoint Modulators
- Industry Trends - Cytokines
- Industry Trends - Oncolytic Viruses
- Regulatory Trends
- Value Chain
- Immuno-oncology Value Chain
- Bispecific Antibodies
- Bispecific Antibodies - KOL Perspective
- Cancer Vaccines
- Cancer Vaccines - KOL Perspective
- Cell Therapies
- Cell Therapies - KOLs Perspective
- Checkpoint Modulators
- Checkpoint Modulators - KOL Perspective
- Next-generation Cytokines
- Cytokines - KOL Perspective
- Oncolytic Viruses
- Oncolytic Viruses - KOL Perspective
- Immuno-oncology in Clinical Trials
- Marketed Products
- Ten new immune checkpoint inhibitors were approved in just over one year, most in China
- Total Market Size for Immuno-oncology Agents
- 10 Highest-Grossing Immuno-oncology Treatments in 2021
- Leading Checkpoint Modulators in the 8MM
- Checkpoint Modulator Treatments - KOL Perspective
- Leading Checkpoint Modulators in the 8MM
- Checkpoint Modulator Treatments - KOL Perspective
- Leading Cancer Vaccines, Bispecific Antibodies, and Oncolytic Viruses in the 8MM
- Bispecific Antibody, Cancer Vaccine, or Oncolytic Virus Treatments - KOL Perspective
- Leading Cell Therapies in the 8MM
- Cell Therapy Treatments - KOL Perspective
- Leading Cell Therapies in the 8MM
- Pipeline Products
- Immuno-oncology Pipeline Products in the 8MM
- Future Outlook of IO Agents, According to High-Prescribing Physicians
- Consensus Forecast Sales for the Top Three Pipeline Candidates per IO Class
- The Forecast Highest-Grossing Bispecific Antibody Products
- Bispecific Antibody Treatments - KOL Perspective
- The Forecast Highest-Grossing Vaccine Products
- Cancer Vaccine Treatments - KOL Perspective
- The Forecast Highest-Grossing Cell Therapy Products
- Cell Therapy Treatments - KOL Perspective
- The Forecast Highest-Grossing Checkpoint Modulator Products
- Checkpoint Modulator Treatments - KOL Perspective
- The Forecast Highest-Grossing Cytokine Products
- Cytokines - KOL Perspective
- The Forecast Highest-Grossing Oncolytic Virus Products
- Oncolytic Virus Treatments - KOLs Perspective
- Market Analysis
- Market Analysis and Forecast of the Six Classes of IO Agents
- Top 10 Strategic Partnership Deals of the Last Decade by Size in the IO Space
- Latest Strategic Partnership Deals in the IO Space
- Mergers and Acquisitions that Include IO Assets: 2020-2021
- Mergers and Acquisitions that Include IO Assets: 2016-2020
- Regulatory and Market Access
- Immuno-oncology in Clinical Trials
- Clinical Trials
- Differences in Immuno-oncology Clinical Trials - KOL Perspective
- Challenges in Immuno-oncology Clinical Trials - KOL Perspective
- Regulatory and Market Access - US
- Key Market Access and Regulatory Concepts - US
- Market Access - US Payer & KOL Perspective
- Regulatory and Market Access - EU
- Key Market Access and Regulatory Concepts - Europe
- Market Access - EU Payer & KOL Perspective
- Regulatory and Market Access - Japan
- Market Access - Japan KOL Perspective
- Key Market Access and Regulatory Concepts - Japan
- Regulatory and Market Access - China
- Market Access - China KOL Perspective
- Key Market Access and Regulatory Concepts - China
- Early Access Schemes
- Barriers to Access According to High Prescribers
- Opportunities, Challenges, and Unmet Needs
- Bispecific Antibodies
- Cancer Vaccines
- Cancer Vaccines - Additional KOL Perspective
- Cell Therapies
- Cell Therapies - Additional KOL Perspective
- Checkpoint Modulators
- Checkpoint Modulators - Additional KOL Perspective
- Cytokines
- Oncolytic Viruses
- Clinical Unmet Needs in Immuno-oncology - Gap Analysis
- Commercial Unmet Needs in Immuno-oncology - Gap Analysis
- Unmet Needs - KOL Perspective
- Unmet Needs According to High Prescribers
- R&D Strategies
- Opportunities for the Industry - Modern Approaches & Collaboration
- Closing Remarks - In Their Words
- Companies
- Drug Development Scorecard - Immuno-oncology
- Current Major Players - Novartis
- Current Major Players - Merck & Co.
- Current Major Players - Gilead Sciences
- Current Major Players - Roche
- Current Major Players - BMS
- Current Major Players - AstraZeneca
- Current Major Players - Sanofi
- Current Major Players - Amgen
- Current Major Players - Dendreon Pharmaceuticals
- Current Major Players - Legend Biotech
- Current Major Players - Johnson & Johnson
- Future Players Based on Pipeline Strength - Alphamab
- Future Players Based on Pipeline Strength - Genmab
- Future Players Based on Pipeline Strength - Regeneron
- Future Players Based on Pipeline Strength - Iovance Therapeutics
- Future Players Based on Pipeline Strength - Replimune
- Future Players Based on Pipeline Strength - Oncolytics
- Future Players Based on Pipeline Strength - Inovio
- Future Players Based on Pipeline Strength - VBI Vaccines
- Future Players Based on Pipeline Strength - Instil Bio
- Future Players Based on Pipeline Strength - Alaunos Therapeutics
- Future Players Based on Pipeline Strength - Jounce Therapeutics
- Future Players Based on Pipeline Strength - Arcus Biosciences
- Future Players Based on Pipeline Strength - Neoleukin Therapeutics
- Future Players Based on Pipeline Strength - Alkermes
- Future Players Based on Pipeline Strength - Oncosec
- Future Players Based on Pipeline Strength - Oncorus
- Appendix
- Sources
- Primary Research
- Key Themes Impacting the Pharmaceutical Industry
- Our thematic research methodology
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook